Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aligos Therapeutics SEC filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing therapies for liver and viral diseases. Its Form 8-K reports furnish results of operations, business progress updates, clinical and regulatory events for pevifoscorvir sodium, and material agreements such as the exclusive license for development and commercialization in Greater China.
Proxy materials cover annual meeting procedures, stockholder voting matters, board governance, and compensation-related disclosures. Other current reports document executive officer appointments, compensatory arrangements, exhibit filings, and the company’s common stock listed on the Nasdaq Capital Market under ALGS.
Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.
- Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
- Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
- All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
- Shares outstanding on record date: 5,314,801.
The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.